PHATHOM PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
PHATHOM PHARMACEUTICALS, INC. (PHAT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 615.05 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-07-30
- PHATHOM PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 504.69K shares, a 44.53% decline year-over-year.
- PHATHOM PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 110.36K shares, a 71.82% increase year-over-year.
- PHATHOM PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 157.81K shares, a 32.06% decline year-over-year.
- PHATHOM PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 241.36K shares, a 181.00% increase year-over-year.
- PHATHOM PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 1.37M shares, a 151.66% increase from fiscal 2024.
- PHATHOM PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 545.68K shares, a 78.13% decline from fiscal 2023.
- PHATHOM PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 2.49M shares, a 629.09% increase from fiscal 2022.
- PHATHOM PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 342.19K shares, a 114.30% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 504.69K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | 615.05K shares 10-Q · filed 2026-07-30 | 772.86K shares derived: sum of 3 quarters · filed 2026-07-30 | 1.01M shares derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | 110.36K shares 10-Q · filed 2026-04-30 | 268.17K shares derived: sum of 2 quarters · filed 2026-04-30 | 509.53K shares derived: sum of 3 quarters · filed 2026-04-30 | 1.42M shares derived: sum of 4 quarters · filed 2026-04-30 |
| 2025-12-31 | 157.81K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 399.17K shares derived: sum of 2 quarters · filed 2026-02-26 | 1.31M shares derived: sum of 3 quarters · filed 2026-02-26 | 1.37M shares 10-K · filed 2026-02-26 |
| 2025-09-30 | 241.36K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | 1.15M shares derived: sum of 2 quarters · filed 2025-10-30 | 1.22M shares 10-Q · filed 2025-10-30 | 1.45M shares derived: sum of 4 quarters · filed 2025-10-30 |
| 2025-06-30 | 909.86K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 974.09K shares 10-Q · filed 2025-08-07 | 1.21M shares derived: sum of 3 quarters · filed 2025-08-07 | 1.29M shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | 64.23K shares 10-Q · filed 2025-05-01 | 296.50K shares derived: sum of 2 quarters · filed 2025-05-01 | 382.40K shares derived: sum of 3 quarters · filed 2025-05-01 | 450.25K shares derived: sum of 4 quarters · filed 2025-05-01 |
| 2024-12-31 | 232.27K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | 318.17K shares derived: sum of 2 quarters · filed 2025-03-06 | 386.02K shares derived: sum of 3 quarters · filed 2025-03-06 | 545.68K shares 10-K · filed 2025-03-06 |
| 2024-09-30 | 85.89K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 153.75K shares derived: sum of 2 quarters · filed 2024-11-07 | 313.41K shares 10-Q · filed 2024-11-07 | 368.66K shares derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | 67.85K shares derived: 10-Q 6 month − 10-Q/A 3 month · filed 2024-08-08 | 227.52K shares 10-Q · filed 2024-08-08 | 282.77K shares derived: sum of 3 quarters · filed 2024-08-08 | 2.69M shares derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | 159.67K shares 10-Q/A · filed 2024-06-14 | 214.92K shares derived: sum of 2 quarters · filed 2024-06-14 | 2.62M shares derived: sum of 3 quarters · filed 2024-06-14 | 2.63M shares derived: sum of 4 quarters · filed 2024-06-14 |
| 2023-12-31 | 55.25K shares derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-06-14 | 2.46M shares derived: sum of 2 quarters · filed 2024-06-14 | 2.47M shares derived: sum of 3 quarters · filed 2024-06-14 | 2.49M shares 10-K/A · filed 2024-06-14 |
| 2023-09-30 | 2.41M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 2.41M shares derived: sum of 2 quarters · filed 2023-11-09 | 2.44M shares 10-Q · filed 2023-11-09 | |
| 2023-06-30 | 7.04K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 33.01K shares 10-Q · filed 2023-08-10 | ||
| 2023-03-31 | 25.96K shares 10-Q · filed 2023-05-10 | |||
| 2022-12-31 | 342.19K shares 10-K/A · filed 2024-06-14 | |||
| 2021-12-31 | 52.08K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | 64.58K shares derived: sum of 2 quarters · filed 2022-03-01 | 159.68K shares 10-K · filed 2022-03-01 | |
| 2021-09-30 | 12.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | 107.61K shares 10-Q · filed 2021-11-08 | ||
| 2021-06-30 | 95.11K shares 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |